Patent ID: 8158582
Filing Date: 2012-04-17
Classification: A61K,A61P

Abstract:
1. A method for treating a human pediatric subject having primary insulin-like growth factor-1 deficiency (IGFD) comprising; administering to a human pediatric subject suffering from a growth disorder characterized by primary IGFD and partial endogenous growth hormone signaling a combination of an amount of insulin-like growth factor-1 (IGF-1) and an amount of growth hormone (GH) effective to promote growth in the subject, wherein the subject is further characterized as follows: the subject, at the time of treatment or prior to initial treatment with IGF-1, has or had a height at least about 2.0 standard deviations (SD) below a normal mean for a subject of the same age and gender, and the subject has or had a blood level of IGF-1 below, but not more than about 2 SD below, normal mean levels for a subject of the same age and gender, wherein the subject receives each of IGF-1 and GH in a single administration per day, and wherein the single administration of IGF-1 and the single administration of GH are administered to the patient substantially contemporaneously each day.